{"id":1694,"date":"2020-12-01T12:56:32","date_gmt":"2020-12-01T17:56:32","guid":{"rendered":"http:\/\/carolinaurologicresearchcenter.com\/?p=1694"},"modified":"2020-12-01T13:05:57","modified_gmt":"2020-12-01T18:05:57","slug":"intravesical-nadofaragene-firadenovec-gene-therapy-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-a-single-arm-open-label-repeat-dose-clinical-trial","status":"publish","type":"post","link":"https:\/\/carolinaurologicresearchcenter.com\/intravesical-nadofaragene-firadenovec-gene-therapy-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-a-single-arm-open-label-repeat-dose-clinical-trial\/","title":{"rendered":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial"},"content":{"rendered":"<p>Prof Stephen A Boorjian, MD, Mehrdad Alemozaffar, MD, Prof Badrinath R Konety, MD, Neal D Shore, MD, Prof Leonard G Gomella, MD, Prof Ashish M Kamat, MD, et al.<\/p>\n<p>Background:&nbsp;BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa\/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDNA into the bladder epithelium, and a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. We aimed to evaluate its efficacy in patients with BCG-unresponsive non-muscle-invasive bladder cancer.<\/p>\n<p><a href=\"https:\/\/www.thelancet.com\/pdfs\/journals\/lanonc\/PIIS1470-2045(20)30540-4.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Click here to read more.<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prof Stephen A Boorjian, MD, Mehrdad Alemozaffar, MD, Prof Badrinath R Konety, MD, Neal D Shore, MD, Prof Leonard G Gomella, MD, Prof Ashish M Kamat, MD, et al. Background:&nbsp;BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa\/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1697,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"ngg_post_thumbnail":0,"footnotes":""},"categories":[1],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial - Carolina Urologic Research Center - Myrtle Beach, SC<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/carolinaurologicresearchcenter.com\/intravesical-nadofaragene-firadenovec-gene-therapy-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-a-single-arm-open-label-repeat-dose-clinical-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial - Carolina Urologic Research Center - Myrtle Beach, SC\" \/>\n<meta property=\"og:description\" content=\"Prof Stephen A Boorjian, MD, Mehrdad Alemozaffar, MD, Prof Badrinath R Konety, MD, Neal D Shore, MD, Prof Leonard G Gomella, MD, Prof Ashish M Kamat, MD, et al. Background:&nbsp;BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa\/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/carolinaurologicresearchcenter.com\/intravesical-nadofaragene-firadenovec-gene-therapy-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-a-single-arm-open-label-repeat-dose-clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Carolina Urologic Research Center - Myrtle Beach, SC\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-01T17:56:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-12-01T18:05:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/carolinaurologicresearchcenter.com\/wp-content\/uploads\/Intravesical-nadofaragene-firadenovec-gene-therapy-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"625\" \/>\n\t<meta property=\"og:image:height\" content=\"521\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"CURC\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"CURC\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/intravesical-nadofaragene-firadenovec-gene-therapy-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-a-single-arm-open-label-repeat-dose-clinical-trial\/\",\"url\":\"https:\/\/carolinaurologicresearchcenter.com\/intravesical-nadofaragene-firadenovec-gene-therapy-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-a-single-arm-open-label-repeat-dose-clinical-trial\/\",\"name\":\"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial - Carolina Urologic Research Center - Myrtle Beach, SC\",\"isPartOf\":{\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/intravesical-nadofaragene-firadenovec-gene-therapy-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-a-single-arm-open-label-repeat-dose-clinical-trial\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/intravesical-nadofaragene-firadenovec-gene-therapy-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-a-single-arm-open-label-repeat-dose-clinical-trial\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/carolinaurologicresearchcenter.com\/wp-content\/uploads\/Intravesical-nadofaragene-firadenovec-gene-therapy-1.jpg\",\"datePublished\":\"2020-12-01T17:56:32+00:00\",\"dateModified\":\"2020-12-01T18:05:57+00:00\",\"author\":{\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/#\/schema\/person\/1e494288987b949249fc933d8d93c363\"},\"breadcrumb\":{\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/intravesical-nadofaragene-firadenovec-gene-therapy-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-a-single-arm-open-label-repeat-dose-clinical-trial\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/carolinaurologicresearchcenter.com\/intravesical-nadofaragene-firadenovec-gene-therapy-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-a-single-arm-open-label-repeat-dose-clinical-trial\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/intravesical-nadofaragene-firadenovec-gene-therapy-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-a-single-arm-open-label-repeat-dose-clinical-trial\/#primaryimage\",\"url\":\"https:\/\/carolinaurologicresearchcenter.com\/wp-content\/uploads\/Intravesical-nadofaragene-firadenovec-gene-therapy-1.jpg\",\"contentUrl\":\"https:\/\/carolinaurologicresearchcenter.com\/wp-content\/uploads\/Intravesical-nadofaragene-firadenovec-gene-therapy-1.jpg\",\"width\":625,\"height\":521},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/intravesical-nadofaragene-firadenovec-gene-therapy-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-a-single-arm-open-label-repeat-dose-clinical-trial\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/carolinaurologicresearchcenter.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/#website\",\"url\":\"https:\/\/carolinaurologicresearchcenter.com\/\",\"name\":\"Carolina Urologic Research Center - Myrtle Beach, SC\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/carolinaurologicresearchcenter.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/#\/schema\/person\/1e494288987b949249fc933d8d93c363\",\"name\":\"CURC\",\"url\":\"https:\/\/carolinaurologicresearchcenter.com\/author\/curc\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial - Carolina Urologic Research Center - Myrtle Beach, SC","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/carolinaurologicresearchcenter.com\/intravesical-nadofaragene-firadenovec-gene-therapy-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-a-single-arm-open-label-repeat-dose-clinical-trial\/","og_locale":"en_US","og_type":"article","og_title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial - Carolina Urologic Research Center - Myrtle Beach, SC","og_description":"Prof Stephen A Boorjian, MD, Mehrdad Alemozaffar, MD, Prof Badrinath R Konety, MD, Neal D Shore, MD, Prof Leonard G Gomella, MD, Prof Ashish M Kamat, MD, et al. Background:&nbsp;BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa\/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon [&hellip;]","og_url":"https:\/\/carolinaurologicresearchcenter.com\/intravesical-nadofaragene-firadenovec-gene-therapy-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-a-single-arm-open-label-repeat-dose-clinical-trial\/","og_site_name":"Carolina Urologic Research Center - Myrtle Beach, SC","article_published_time":"2020-12-01T17:56:32+00:00","article_modified_time":"2020-12-01T18:05:57+00:00","og_image":[{"width":625,"height":521,"url":"https:\/\/carolinaurologicresearchcenter.com\/wp-content\/uploads\/Intravesical-nadofaragene-firadenovec-gene-therapy-1.jpg","type":"image\/jpeg"}],"author":"CURC","twitter_card":"summary_large_image","twitter_misc":{"Written by":"CURC"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/carolinaurologicresearchcenter.com\/intravesical-nadofaragene-firadenovec-gene-therapy-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-a-single-arm-open-label-repeat-dose-clinical-trial\/","url":"https:\/\/carolinaurologicresearchcenter.com\/intravesical-nadofaragene-firadenovec-gene-therapy-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-a-single-arm-open-label-repeat-dose-clinical-trial\/","name":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial - Carolina Urologic Research Center - Myrtle Beach, SC","isPartOf":{"@id":"https:\/\/carolinaurologicresearchcenter.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/carolinaurologicresearchcenter.com\/intravesical-nadofaragene-firadenovec-gene-therapy-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-a-single-arm-open-label-repeat-dose-clinical-trial\/#primaryimage"},"image":{"@id":"https:\/\/carolinaurologicresearchcenter.com\/intravesical-nadofaragene-firadenovec-gene-therapy-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-a-single-arm-open-label-repeat-dose-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/carolinaurologicresearchcenter.com\/wp-content\/uploads\/Intravesical-nadofaragene-firadenovec-gene-therapy-1.jpg","datePublished":"2020-12-01T17:56:32+00:00","dateModified":"2020-12-01T18:05:57+00:00","author":{"@id":"https:\/\/carolinaurologicresearchcenter.com\/#\/schema\/person\/1e494288987b949249fc933d8d93c363"},"breadcrumb":{"@id":"https:\/\/carolinaurologicresearchcenter.com\/intravesical-nadofaragene-firadenovec-gene-therapy-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-a-single-arm-open-label-repeat-dose-clinical-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/carolinaurologicresearchcenter.com\/intravesical-nadofaragene-firadenovec-gene-therapy-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-a-single-arm-open-label-repeat-dose-clinical-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/carolinaurologicresearchcenter.com\/intravesical-nadofaragene-firadenovec-gene-therapy-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-a-single-arm-open-label-repeat-dose-clinical-trial\/#primaryimage","url":"https:\/\/carolinaurologicresearchcenter.com\/wp-content\/uploads\/Intravesical-nadofaragene-firadenovec-gene-therapy-1.jpg","contentUrl":"https:\/\/carolinaurologicresearchcenter.com\/wp-content\/uploads\/Intravesical-nadofaragene-firadenovec-gene-therapy-1.jpg","width":625,"height":521},{"@type":"BreadcrumbList","@id":"https:\/\/carolinaurologicresearchcenter.com\/intravesical-nadofaragene-firadenovec-gene-therapy-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-a-single-arm-open-label-repeat-dose-clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/carolinaurologicresearchcenter.com\/"},{"@type":"ListItem","position":2,"name":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial"}]},{"@type":"WebSite","@id":"https:\/\/carolinaurologicresearchcenter.com\/#website","url":"https:\/\/carolinaurologicresearchcenter.com\/","name":"Carolina Urologic Research Center - Myrtle Beach, SC","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/carolinaurologicresearchcenter.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/carolinaurologicresearchcenter.com\/#\/schema\/person\/1e494288987b949249fc933d8d93c363","name":"CURC","url":"https:\/\/carolinaurologicresearchcenter.com\/author\/curc\/"}]}},"_links":{"self":[{"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/posts\/1694"}],"collection":[{"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/comments?post=1694"}],"version-history":[{"count":0,"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/posts\/1694\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/media\/1697"}],"wp:attachment":[{"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/media?parent=1694"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/categories?post=1694"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/tags?post=1694"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}